Peptide LexiconAll compounds

Bronchogen (Ala-Glu-Asp-Leu): The 'Lung Bioregulator' Tetrapeptide — Rat COPD Models, Cell Cultures and a Sequence the Papers Disagree On

Bronchogen is the synthetic tetrapeptide Ala-Glu-Asp-Leu (AEDL) from the St Petersburg bioregulator series, presented for the bronchi and lungs. PubMed holds seven records naming it: two rat models of obstructive lung disease, cell cultures and DNA chemistry. One 2011 paper prints the sequence with two residues swapped. No trial in people is registered.

Experimental onlyNo trial registeredTwo rat lung studies

Caroline S · Published 2026-11-19

Length

4 amino acids — C18H30N4O9, molecular weight 446.5 (PubChem CID 11690869)

Sequence

AEDL (Ala-Glu-Asp-Leu), as given by PubChem and by PMID 22808515; a 2011 paper's title prints Ala-Asp-Glu-Leu (PMID 21240358)

Origin

Synthetic; one of the short peptides of the St Petersburg bioregulator series associated with V. Khavinson

Last reviewed

2026-11-19

What is it good for?

It is presented as a bioregulator for the bronchi and lungs. The two studies that test that are in rats with a lung disease induced by breathing nitrogen dioxide, where a month of Bronchogen was reported to restore the airway lining and lower inflammation. The rest of the record is cell cultures, DNA-binding chemistry and, oddly, tobacco plants. No study in people was found.

Illustration: A clear glass vial with white powder on a light wooden surface, with a deep green reflection.
Illustration

What it is

Bronchogen is a man-made tetrapeptide whose chain reads Ala-Glu-Asp-Leu — alanine, glutamic acid, aspartic acid, leucine. It belongs to the St Petersburg series of short "bioregulator" peptides associated with V. Khavinson, each named for an organ — this one for the bronchi. A 2023 docking study from the same programme lists it, as AEDL, among 26 "biologically active ultrashort peptides" (PMID 36979488).

Property Value Source
Sequence Ala-Glu-Asp-Leu (AEDL) PubChem; PMID 22808515
Length 4 amino acids —
Formula C18H30N4O9 PubChem CID 11690869
Molecular weight 446.5 PubChem

A sequence the papers disagree on. The title of a 2011 paper reads "Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability" (Monaselidze et al., PMID 21240358). PubChem's structure for "bronchogen" and a 2012 paper with Khavinson as first author give Ala-Glu-Asp-Leu. Swapping two residues makes a different molecule; this entry follows PubChem and the 2012 paper, and the 2011 order is labelled here as a discrepancy rather than resolved.

The family resemblance. The heart-labelled Cardiogen is Ala-Glu-Asp-Arg and the brain-labelled Cortagen is Ala-Glu-Asp-Pro: the three differ only in the last amino acid.

What PubMed holds

Searched by name on 2026-11-19, PubMed returns just seven papers, spanning 2006–2017, and Khavinson co-signs four of them.

Year What was studied People given the peptide?
2006 Organ-type tissue cultures from young and old rats (PMID 17152728, title) No
2011 DNA melting in calorimetry (PMID 21240358) No
2011 Fluorescent peptides entering HeLa cell nuclei (PMID 22117547, title) No
2012 Human embryonic bronchial cells in culture (PMID 22808515) No — cells only
2015 Rat model of obstructive lung disease (PMID 26468022) No
2017 Rat model of obstructive lung disease (PMID 30199201) No
2017 Gene expression in tobacco plants (PMID 28371610, title) No

The lung studies are in rats. A team at the Pavlov First St Petersburg State Medical University's pulmonology institute exposed rats intermittently to nitrogen dioxide for 60 days to model chronic obstructive pulmonary disease. After a month of Bronchogen, they report the airway lining lost the features of the disease — goblet-cell hyperplasia, squamous metaplasia, lymphocyte infiltration, emphysema — and ciliated cells returned; secretory IgA rose and neutrophil inflammation fell (Kuzubova et al. 2015, PMID 26468022; Titova et al. 2017, PMID 30199201, which adds surfactant protein B). The abstracts do not give the dose or the number of rats.

In cell culture, Bronchogen raised the differentiation markers CXCL12 and Hoxa3 in human embryonic bronchial cells, more in late-passage "aging" cultures than in young ones (Khavinson et al. 2012, PMID 22808515). The same paper ran Pancragen (Lys-Glu-Asp-Trp) on pancreatic cells and Vesugen on prostate fibroblasts.

A detail the name search misses: searched by its sequence rather than its name, five of the 12 PubMed records for AEDL are about the roots of tobacco plants (2017–2026, e.g. PMID 39796141), where the peptide was tested as a growth signal.

What is not established

  • Any effect in people. No record reports a lung outcome, symptom or measurement in a person, and ClinicalTrials.gov lists no study (2026-11-19).
  • Dose and route in the rat studies, which the abstracts do not give.
  • Independent replication outside St Petersburg. The two rat studies come from a separate St Petersburg institute; no group elsewhere has reported a lung study.
  • Safety. No study reports giving it to anyone.

Where it stands

For a peptide named after the airways, the lung evidence amounts to two experiments in rats breathing nitrogen dioxide, and nothing in a person. Cough, breathlessness and diagnosed lung disease are matters for a respiratory clinician; this entry records the sequence, the papers and the gaps. Related entries: Cardiogen, Cortagen, Prostamax, Pinealon.

Sources opened 2026-11-19: PubChem (CID 11690869); PubMed E-utilities (searches; abstracts of PMIDs 21240358, 26468022, 30199201, 22808515, 36979488; titles of the others); ClinicalTrials.gov API v2.

What the research shows

Repairs airway lining in obstructive lung disease

Kuzubova et al. 2015, Bull Exp Biol Med (PMID 26468022) and Titova et al. 2017 (PMID 30199201): rats exposed to NO2 intermittently for 60 days, then given Bronchogen for 1 month

Stimulates differentiation of aging bronchial cells

Khavinson et al. 2012 (PMID 22808515): cultures of human embryonic bronchial epithelial cells; markers CXCL12 and Hoxa3 rose more in late-passage cultures

Binds DNA

Monaselidze et al. 2011 (PMID 21240358): DNA melting temperature rose 3.1 °C in calorimetry with calf-thymus and mouse-liver DNA

Treats COPD or asthma in people

No study found. PubMed: 0 of the 7 records report a human lung outcome (2026-11-19)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

Nothing found — Drugs@FDA returns no bronchogen product and the PubMed papers describe it only as an experimental peptide (2026-11-19).

Trials

ClinicalTrials.gov: no study of bronchogen. Its single hit (NCT00746759, an airway gene-expression study) does not test the peptide (2026-11-19).

Published record

PubMed: 7 records with 'bronchogen' in title or abstract, 2006–2017; 12 for 'AEDL' or 'Ala-Glu-Asp-Leu' with 'peptide', five of them on tobacco roots (2026-11-19).

Frequently asked questions

What is Bronchogen?

A lab-made chain of four residues, Ala-Glu-Asp-Leu (AEDL). The St Petersburg bioregulator programme names each of its short peptides after an organ, and gave this one to the bronchi.

What is Bronchogen said to be good for?

The lungs and airways. The only studies that test that are two rat experiments with a nitrogen-dioxide model of chronic obstructive lung disease. No study in people was found.

Has Bronchogen been tested in humans?

No. One study used human embryonic bronchial cells grown in culture; no person was given the peptide, and no trial is registered on ClinicalTrials.gov.

Why do some papers write the sequence differently?

A 2011 paper's title gives Ala-Asp-Glu-Leu, with the middle two amino acids swapped. PubChem and a 2012 paper from the same programme give Ala-Glu-Asp-Leu. The two orders are different molecules; this entry follows PubChem and labels the discrepancy.

Is Bronchogen the same as Cardiogen or Cortagen?

No, though all three start Ala-Glu-Asp. Cardiogen ends in arginine, Cortagen in proline and Bronchogen in leucine.

Is Bronchogen approved?

Not by any regulator this entry could find: Drugs@FDA is silent on it, and the seven PubMed papers mention no licence anywhere.